Profile data is unavailable for this security.
About the company
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
- Revenue in ILS (TTM)0.00
- Net income in ILS-12.01m
- Incorporated2008
- Employees32.00
- LocationKadimastem Ltd.Pinchas Sapir 7, Weizmann Science ParkNESS-ZIONA 74140IsraelISR
- Phone+972 89100695
- Fax+972 89100698
- Websitehttps://www.kadimastem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merchavia Holdings and Investments Ltd | 460.00k | -16.23m | 13.94m | 1.23k | -- | 0.4825 | -- | 30.31 | -3.87 | -3.87 | 0.0409 | 1.72 | 0.0121 | -- | 1.53 | 374.59 | -42.78 | -3.37 | -43.98 | -3.46 | -- | -- | -3,528.48 | -185.15 | -- | -0.1346 | 0.00 | -- | 90.08 | -10.25 | -349.99 | -- | 37.97 | -- |
Nextage Therapeutics Ltd | 876.00k | -4.07m | 21.29m | -- | -- | -- | -- | 24.31 | -0.1396 | -0.1396 | 0.03 | -0.0958 | 0.672 | -- | 6.82 | -- | -322.44 | -188.94 | -- | -423.76 | 25.68 | 33.33 | -479.79 | -2,486.19 | -- | -18.46 | -- | -- | -- | 17.99 | 27.21 | -- | -- | -- |
Kadimastem Ltd | 0.00 | -12.01m | 26.11m | 32.00 | -- | -- | -- | -- | -1.22 | -1.22 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -115.17 | -155.33 | -1,153.60 | -1,831.12 | -- | -- | -- | -- | -- | -9.44 | 3.22 | -- | -- | -- | 47.14 | -- | -50.73 | -- |
Purple Biotech Ltd | 0.00 | -67.90m | 47.78m | 20.00 | -- | 0.3811 | -- | -- | -0.2679 | -0.2679 | 0.00 | 0.4086 | 0.00 | -- | -- | 0.00 | -40.57 | -37.24 | -47.99 | -41.28 | -- | -- | -- | -9,415.70 | -- | -- | 0.0098 | -- | -- | -- | 8.25 | -- | -28.45 | -- |
X T L Biopharmaceuticals Ltd | 1.64m | -81.38m | 48.73m | 33.00 | -- | 0.599 | -- | 29.66 | -0.3695 | -0.3695 | 0.0075 | 0.1493 | 0.0192 | -- | 0.7012 | 49,784.54 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
Matricelf Ltd | 0.00 | -13.83m | 57.22m | -- | -- | 2.12 | -- | -- | -0.8777 | -0.8777 | 0.00 | 1.67 | 0.00 | -- | -- | -- | -39.69 | -- | -42.80 | -- | -- | -- | -- | -- | -- | -- | 0.0527 | -- | -- | -- | -10.77 | -- | -- | -- |
DNA Group TR Ltd | 306.00k | -1.18m | 87.20m | 14.00 | -- | 1.10 | -- | 284.97 | -0.0088 | -0.0088 | 0.0025 | 0.6429 | 0.0038 | -- | 1.37 | 21,857.14 | -1.45 | -23.54 | -1.46 | -26.27 | -- | -- | -384.64 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
Data as of Jul 16 2024. Currency figures normalised to Kadimastem Ltd.'s reporting currency: Israeli Shekel ILS
0.11%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
Altshuler Shaham Mutual Funds Management Ltd.as of 30 Apr 2024 | 4.71k | 0.11% |
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.